VITLrx, Inc.

VITLrx, Inc. is a U. S. -based company providing e-prescribing solutions and innovative therapeutic products aimed at treating significant medical conditions, particularly in oncology and autoimmune disorders.

Founded in 2024 in Nashville, US, VITLrx, Inc. focuses on therapeutic development and e-prescribing technology. The company has successfully completed one deal, raising USD 7. 5 mn in a SERIES A round led by SignalFire on March 25, 2026.

This funding brings the total amount raised to USD 7. 5 mn with a current valuation of USD 26. 21 mn. VITLrx specializes in developing innovative therapeutic solutions aimed at addressing significant unmet medical needs.

Their core product offerings include a range of proprietary formulations designed to target specific diseases and conditions, enhancing treatment efficacy and patient outcomes. These products are particularly focused on treatment areas such as oncology and autoimmune disorders, providing patients with advanced options that are often not available through traditional therapies. VITLrx serves a diverse client base that includes hospitals, specialty clinics, and healthcare providers across various regions, particularly in North America and parts of Europe. These therapeutic solutions are aimed at improving the quality of life for patients by offering tailored treatment regimes that leverage cutting-edge scientific research and development.

VITLrx's revenue model primarily revolves around a combination of direct sales and strategic partnerships within the healthcare ecosystem. The company engages in B2B transactions, supplying its products to hospitals and healthcare providers who utilize these advanced therapies in clinical settings. Revenue is generated through the sale of their flagship products, which are typically offered under structured pricing plans that reflect their innovative nature and the benefits they provide. These plans may include bundled pricing for multiple therapies or tiered pricing based on volume, ensuring that clients benefit from economies of scale.

By aligning their pricing strategy with the value delivered to healthcare providers and ultimately to patients, VITLrx reinforces its commitment to improving health outcomes while maintaining a sustainable revenue stream. VITLrx plans to expand its e-prescribing platform and pharmacy network while supporting product development and team expansion for cash-pay clinics. The recent SERIES A funding of USD 7. 5 mn will be pivotal in achieving these goals.

The company targets the launch of new therapeutic products and initiatives aimed at enhancing patient care by 2026, with specific plans to enter new markets in North America and Europe.